China National Biotec Group announced its COVID-19 vaccine candidate has triggered antibodies in clinical trials and the company plans late-stage clinical trials in foreign countries, as reported in Fidelity.
According to the preliminary data from 1120 healthy participants, the vaccine, developed by a Wuhan-based research institute affiliated to CNBG's parent company Sinopharm, was found to have induced high-level antibodies in all inoculated people without adverse effects.
CNBG said it is proactively seeking opportunities for Phase 3 trials overseas, adding that it has "secured cooperative intent with companies and institutes in many countries."
Meanwhile, Sinovac Biotech released recently positive preliminary clinical trial results for its potential vaccine candidate, which is expected to be tested in a Phase III trial in Brazil.
To read more NewsPoints articles, click here.